BMX-003
/ Biomunex
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 07, 2026
A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma
(clinicaltrials.gov)
- P1/2 | N=15 | Recruiting | Sponsor: Novelwise Pharmaceutical Corporation
New P1/2 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1